1. Home
  2. VRCA vs DLNG Comparison

VRCA vs DLNG Comparison

Compare VRCA & DLNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Verrica Pharmaceuticals Inc.

VRCA

Verrica Pharmaceuticals Inc.

HOLD

Current Price

$5.85

Market Cap

137.3M

Sector

Health Care

ML Signal

HOLD

Logo Dynagas LNG Partners LP

DLNG

Dynagas LNG Partners LP

HOLD

Current Price

$3.53

Market Cap

142.3M

ML Signal

HOLD

Company Overview

Basic Information
Metric
VRCA
DLNG
Founded
2013
2013
Country
United States
Greece
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Marine Transportation
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
137.3M
142.3M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
VRCA
DLNG
Price
$5.85
$3.53
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$17.00
N/A
AVG Volume (30 Days)
29.4K
29.0K
Earning Date
05-11-2026
05-26-2026
Dividend Yield
N/A
5.18%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$35,577,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$94.44
$1.10
P/E Ratio
N/A
$3.04
Revenue Growth
370.22
N/A
52 Week Low
$0.52
$3.40
52 Week High
$9.82
$4.45

Technical Indicators

Market Signals
Indicator
VRCA
DLNG
Relative Strength Index (RSI) 43.26 29.50
Support Level $5.32 $3.45
Resistance Level $6.48 $3.86
Average True Range (ATR) 0.48 0.10
MACD -0.01 -0.02
Stochastic Oscillator 8.33 3.78

Price Performance

Historical Comparison
VRCA
DLNG

About VRCA Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.

About DLNG Dynagas LNG Partners LP

Dynagas LNG Partners LP is a limited partnership company focused on owning and operating high specification and versatile LNG carriers that are employed on multi-year contracts with international energy companies, providing the benefits of stable cash flows and high utilization rates. The company defines charters of two years or more as multi-year charters. Its current LNG Carrier fleet is optimized for trading flexibility. In addition to conventional trade, part of LNG Carrier fleet is assigned with Ice Class 1A FS notation and is winterized, which enables trade in subzero and ice bound conditions.

Share on Social Networks: